NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JAPIC ID: JapicCTI-121775

Registered date:

Basic Information

Recruitment status
Health condition(s) or Problem(s) studiedpsoriasis
Date of first enrollment
Target sample size
Countries of recruitment
Study typeINTERVENTIONAL
Intervention(s)Intervention name : Secukinumab INN of the intervention : Secukinumab Dosage And administration of the intervention : Intravenous injection and subcutaneous injection Control intervention name : null

Outcome(s)

Primary OutcomePASI 75, IGA
Secondary OutcomePASI 50/75/90/100, IGA

Key inclusion & exclusion criteria

Age minimum18
Age maximum
GenderBOTH
Include criteria-Subjects must have participated in the study CAIN457A2304 and have achieved a partial response after twelve weeks of treatment with no major protocol deviations. A partial response is defined as having achieved >= PASI 50 but < 75 response.
Exclude criteria-Forms of psoriasis other than chronic plaque -type -Previous exposure to any biologic drug directly targeting IL-17 or the IL-17 receptor, except secukinumab in study CAIN457A2304

Related Information

Contact

public contact
Name Novartis Pharma K.K. Novartis Direct
Address 0120-003-293
Telephone
E-mail
Affiliation
scientific contact
Name
Address
Telephone
E-mail
Affiliation